ROIV Stock Summary and Trading Ideas (Roivant Sciences Ltd. - Common Shares | NASDAQ:ROIV)

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.

As of January 21, 2025, ROIV stock price climbed to $11.27 with 4,019,785 million shares trading.

ROIV has a beta of 0.89, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.11 to the broad based SPY ETF.

ROIV has a market cap of $8.20 billion. This is considered a Mid Cap stock.

In the last 3 years, ROIV traded as high as $13.24 and as low as $2.52.

The top ETF exchange traded funds that ROIV belongs to (by Net Assets): VTI, IJH, VB, XBI, VBK.

ROIV has underperformed the market in the last year with a price return of +4.7% while the SPY ETF gained +29.2%. ROIV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.4% and -3.6%, respectively, while the SPY returned +3.9% and +1.9%, respectively.

ROIV support price is $10.89 and resistance is $11.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.